US20180161327A1 - Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 - Google Patents
Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 Download PDFInfo
- Publication number
- US20180161327A1 US20180161327A1 US15/872,307 US201815872307A US2018161327A1 US 20180161327 A1 US20180161327 A1 US 20180161327A1 US 201815872307 A US201815872307 A US 201815872307A US 2018161327 A1 US2018161327 A1 US 2018161327A1
- Authority
- US
- United States
- Prior art keywords
- fgfr3
- antagonist
- growth
- mutant
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 title claims abstract description 172
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 title claims abstract description 172
- 239000005557 antagonist Substances 0.000 title claims description 44
- 230000004913 activation Effects 0.000 title abstract description 17
- 230000002265 prevention Effects 0.000 title abstract description 6
- 230000002159 abnormal effect Effects 0.000 title abstract description 5
- 101150025764 FGFR3 gene Proteins 0.000 title description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 208000008919 achondroplasia Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 206010008723 Chondrodystrophy Diseases 0.000 claims description 12
- 201000010072 hypochondroplasia Diseases 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 201000003896 thanatophoric dysplasia Diseases 0.000 claims description 9
- 208000007326 Muenke Syndrome Diseases 0.000 claims description 7
- 201000001079 SADDAN Diseases 0.000 claims description 5
- 208000017601 Severe achondroplasia-developmental delay-acanthosis nigricans syndrome Diseases 0.000 claims description 5
- 206010066946 Craniofacial dysostosis Diseases 0.000 claims description 3
- 201000006526 Crouzon syndrome Diseases 0.000 claims description 3
- 201000010272 acanthosis nigricans Diseases 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 abstract description 37
- 210000000689 upper leg Anatomy 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 37
- DXCUKNQANPLTEJ-UHFFFAOYSA-N PD173074 Chemical compound CC(C)(C)NC(=O)NC1=NC2=NC(NCCCCN(CC)CC)=NC=C2C=C1C1=CC(OC)=CC(OC)=C1 DXCUKNQANPLTEJ-UHFFFAOYSA-N 0.000 description 35
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 description 28
- 210000001612 chondrocyte Anatomy 0.000 description 28
- 210000004349 growth plate Anatomy 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 25
- 230000026731 phosphorylation Effects 0.000 description 18
- 238000006366 phosphorylation reaction Methods 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000012010 growth Effects 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 206010072610 Skeletal dysplasia Diseases 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- 108050006400 Cyclin Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 12
- 206010013883 Dwarfism Diseases 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 10
- 235000018417 cysteine Nutrition 0.000 description 10
- 230000001969 hypertrophic effect Effects 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 230000008468 bone growth Effects 0.000 description 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 8
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 8
- 102000030746 Collagen Type X Human genes 0.000 description 7
- 108010022510 Collagen Type X Proteins 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 102000006311 Cyclin D1 Human genes 0.000 description 6
- 108010058546 Cyclin D1 Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 6
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 229940126864 fibroblast growth factor Drugs 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000003032 molecular docking Methods 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 5
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000035194 endochondral ossification Effects 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 238000003365 immunocytochemistry Methods 0.000 description 5
- 238000007901 in situ hybridization Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 102100028233 Coronin-1A Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102200143292 rs121913105 Human genes 0.000 description 4
- 102200143271 rs121913485 Human genes 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000035578 autophosphorylation Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000002297 mitogenic effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 102200143295 rs78311289 Human genes 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 description 2
- XSCUPEOIIXOIAJ-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCN5CCN(C)CC5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCN5CCN(C)CC5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 XSCUPEOIIXOIAJ-UHFFFAOYSA-N 0.000 description 2
- NEJSFALCECFAEE-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCCCC4=CN(C5CCN(CC6=CC=CC=C6)C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCCCC4=CN(C5CCN(CC6=CC=CC=C6)C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 NEJSFALCECFAEE-UHFFFAOYSA-N 0.000 description 2
- VBDAZZGRUFQBQX-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCCCCC4=CN(CC5=NC=CC=C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCCCCC4=CN(CC5=NC=CC=C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 VBDAZZGRUFQBQX-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000009283 Craniosynostoses Diseases 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000961040 Homo sapiens Atrial natriuretic peptide receptor 2 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102220644270 Tartrate-resistant acid phosphatase type 5_N262H_mutation Human genes 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 208000025261 autosomal dominant disease Diseases 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000006552 constitutive activation Effects 0.000 description 2
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000002745 epiphysis Anatomy 0.000 description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 2
- 238000009578 growth hormone therapy Methods 0.000 description 2
- 239000003630 growth substance Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000021332 multicellular organism growth Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- -1 rRNA Proteins 0.000 description 2
- 102220005680 rs121913114 Human genes 0.000 description 2
- 102220005681 rs121913115 Human genes 0.000 description 2
- 102220005682 rs121913116 Human genes 0.000 description 2
- 102200143272 rs121913479 Human genes 0.000 description 2
- 102200143269 rs121913482 Human genes 0.000 description 2
- 102200143273 rs121913484 Human genes 0.000 description 2
- 102220005678 rs28928868 Human genes 0.000 description 2
- 102200143281 rs28931614 Human genes 0.000 description 2
- 102200143275 rs28933068 Human genes 0.000 description 2
- 102200143267 rs4647924 Human genes 0.000 description 2
- 102200143293 rs78311289 Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- AZQVQYSACAFWEU-UHFFFAOYSA-N C#CCCCCNC1=NC=C2C=C(C3=CC(OC)=CC(OC)=C3)C(NC(=O)NC(C)(C)C)=NC2=N1 Chemical compound C#CCCCCNC1=NC=C2C=C(C3=CC(OC)=CC(OC)=C3)C(NC(=O)NC(C)(C)C)=NC2=N1 AZQVQYSACAFWEU-UHFFFAOYSA-N 0.000 description 1
- UPSXBPQTVVXSOQ-UHFFFAOYSA-N C#CCCCNC1=NC=C2C=C(C3=CC(OC)=CC(OC)=C3)C(NC(=O)NC(C)(C)C)=NC2=N1 Chemical compound C#CCCCNC1=NC=C2C=C(C3=CC(OC)=CC(OC)=C3)C(NC(=O)NC(C)(C)C)=NC2=N1 UPSXBPQTVVXSOQ-UHFFFAOYSA-N 0.000 description 1
- 108091007381 CBL proteins Proteins 0.000 description 1
- FSDZFXFFTYRIEY-UHFFFAOYSA-N CC(C)(C)NC(Nc1nc2nc(NCc3c[n](CCN(CC4)CCN4c4ccc(C(F)(F)F)cn4)nn3)ncc2cc1-c1cc(OC)cc(OC)c1)=O Chemical compound CC(C)(C)NC(Nc1nc2nc(NCc3c[n](CCN(CC4)CCN4c4ccc(C(F)(F)F)cn4)nn3)ncc2cc1-c1cc(OC)cc(OC)c1)=O FSDZFXFFTYRIEY-UHFFFAOYSA-N 0.000 description 1
- LJQYAVSTCHESEI-UHFFFAOYSA-N CCN(C(=O)NC1=CC(OC)=CC(OC)=C1Cl)C1=NC=NC(NC2=CC=C(N3CCN(C)CC3)C=C2)=C1 Chemical compound CCN(C(=O)NC1=CC(OC)=CC(OC)=C1Cl)C1=NC=NC(NC2=CC=C(N3CCN(C)CC3)C=C2)=C1 LJQYAVSTCHESEI-UHFFFAOYSA-N 0.000 description 1
- RBKPYMIQFWNBLB-UHFFFAOYSA-N CCN(CC)CCN1C=C(CNC2=NC=C3C=C(C4=CC(OC)=CC(OC)=C4)C(NC(=O)NC(C)(C)C)=NC3=N2)N=N1 Chemical compound CCN(CC)CCN1C=C(CNC2=NC=C3C=C(C4=CC(OC)=CC(OC)=C4)C(NC(=O)NC(C)(C)C)=NC3=N2)N=N1 RBKPYMIQFWNBLB-UHFFFAOYSA-N 0.000 description 1
- MAYIXESJSMZIQJ-UHFFFAOYSA-N CCN1CCC(C2=CC=C(NC3=CC(N(C)C(=O)NC4=C(Cl)C(OC)=CC(OC)=C4Cl)=NC=N3)C=C2)CC1 Chemical compound CCN1CCC(C2=CC=C(NC3=CC(N(C)C(=O)NC4=C(Cl)C(OC)=CC(OC)=C4Cl)=NC=N3)C=C2)CC1 MAYIXESJSMZIQJ-UHFFFAOYSA-N 0.000 description 1
- PDPNFGRXUVHPKA-UHFFFAOYSA-N CCN1CCN(C2=CC=C(NC3=CC(N(C)C(=O)NC4=C(Cl)C(C)=CC(OC)=C4Cl)=NC=N3)C=C2)CC1 Chemical compound CCN1CCN(C2=CC=C(NC3=CC(N(C)C(=O)NC4=C(Cl)C(C)=CC(OC)=C4Cl)=NC=N3)C=C2)CC1 PDPNFGRXUVHPKA-UHFFFAOYSA-N 0.000 description 1
- WGLWYJYJOYCLKX-UHFFFAOYSA-N COC1=CC(NC(=O)N(C)C2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=CC(OC)=C1 Chemical compound COC1=CC(NC(=O)N(C)C2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=CC(OC)=C1 WGLWYJYJOYCLKX-UHFFFAOYSA-N 0.000 description 1
- ZKXNIXASIHIFMC-UHFFFAOYSA-N COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=C(CCCN(C)C)C=C3)=C2)=C1Cl Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=C(CCCN(C)C)C=C3)=C2)=C1Cl ZKXNIXASIHIFMC-UHFFFAOYSA-N 0.000 description 1
- LHWUQEWJSRQLDB-UHFFFAOYSA-N COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=C1 Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=C1 LHWUQEWJSRQLDB-UHFFFAOYSA-N 0.000 description 1
- YCXMKEVLJQGEKJ-UHFFFAOYSA-N COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=C2)=C1Cl Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=C2)=C1Cl YCXMKEVLJQGEKJ-UHFFFAOYSA-N 0.000 description 1
- VJVZPGBCTGRTJD-UHFFFAOYSA-N COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=CC(CN(C)C)=C3)=C2)=C1Cl Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=CC(CN(C)C)=C3)=C2)=C1Cl VJVZPGBCTGRTJD-UHFFFAOYSA-N 0.000 description 1
- NHAXYOVOGZMIOE-UHFFFAOYSA-N COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=CC(CN4CCN(C)CC4)=C3)=C2)=C1Cl Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=CC(CN4CCN(C)CC4)=C3)=C2)=C1Cl NHAXYOVOGZMIOE-UHFFFAOYSA-N 0.000 description 1
- WMASPOZRAFIGIH-UHFFFAOYSA-N COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=CC(N4CCN(C)CC4)=C3)=C2)=C1Cl Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=CC(N4CCN(C)CC4)=C3)=C2)=C1Cl WMASPOZRAFIGIH-UHFFFAOYSA-N 0.000 description 1
- VMWXVTKFWKREIU-UHFFFAOYSA-N COC1=CC(OC)=C(Cl)C(NC(=O)NC2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=C1 Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)NC2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=C1 VMWXVTKFWKREIU-UHFFFAOYSA-N 0.000 description 1
- LIPROJIBSAYCSK-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(C5CCN(CC6=CC=CC=C6)C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(C5CCN(CC6=CC=CC=C6)C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 LIPROJIBSAYCSK-UHFFFAOYSA-N 0.000 description 1
- MVTITHNJSILPKT-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CC5=CC6=C(C=C5)OCO6)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CC5=CC6=C(C=C5)OCO6)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 MVTITHNJSILPKT-UHFFFAOYSA-N 0.000 description 1
- MSSYZEMIPKZMOT-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CC5=CC=C(O)C=C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CC5=CC=C(O)C=C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 MSSYZEMIPKZMOT-UHFFFAOYSA-N 0.000 description 1
- BGDLTWIIVUMTFL-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CC5=NC=CC=C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CC5=NC=CC=C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 BGDLTWIIVUMTFL-UHFFFAOYSA-N 0.000 description 1
- FNQYSGDSORWGBO-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CC5CCCN(C)C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CC5CCCN(C)C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 FNQYSGDSORWGBO-UHFFFAOYSA-N 0.000 description 1
- WLOSSOFYIYUAOV-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCCCC5=CN(CC6CCCN(C)C6)N=N5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCCCC5=CN(CC6CCCN(C)C6)N=N5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 WLOSSOFYIYUAOV-UHFFFAOYSA-N 0.000 description 1
- HHLNLYGUJHKJEF-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCN/C(=N\C(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCN/C(=N\C(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 HHLNLYGUJHKJEF-UHFFFAOYSA-N 0.000 description 1
- BVQCEJDBQGUJGT-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCN5CCCCC5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCN5CCCCC5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 BVQCEJDBQGUJGT-UHFFFAOYSA-N 0.000 description 1
- FNGBUIDBAJCGDD-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCN5CCN(C6=NC=C(C)C=C6)CC5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCN5CCN(C6=NC=C(C)C=C6)CC5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 FNGBUIDBAJCGDD-UHFFFAOYSA-N 0.000 description 1
- BBRMBMKXMVAVIO-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCN5CCN(CCN6C(C)=CC=C6C)CC5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCN5CCN(CCN6C(C)=CC=C6C)CC5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 BBRMBMKXMVAVIO-UHFFFAOYSA-N 0.000 description 1
- PNXNFHYEOVHKPK-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCNC(N)=Cl=N)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCC4=CN(CCNC(N)=Cl=N)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 PNXNFHYEOVHKPK-UHFFFAOYSA-N 0.000 description 1
- UGLCCFDASNUVMR-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCCCC4=CN(CC5=NC=CC=C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCCCC4=CN(CC5=NC=CC=C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 UGLCCFDASNUVMR-UHFFFAOYSA-N 0.000 description 1
- HEUPLQYHAIUUHN-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC3=CN=C(NCCCC4=CN(CC5CCCN(C)C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC3=CN=C(NCCCC4=CN(CC5CCCN(C)C5)N=N4)N=C3N=C2NC(=O)NC(C)(C)C)=C1 HEUPLQYHAIUUHN-UHFFFAOYSA-N 0.000 description 1
- HIBULDBIIVNLNE-UHFFFAOYSA-N COC1=CC=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=C1Cl Chemical compound COC1=CC=C(Cl)C(NC(=O)N(C)C2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=C1Cl HIBULDBIIVNLNE-UHFFFAOYSA-N 0.000 description 1
- NVOHUTVLFUTBHX-UHFFFAOYSA-N COC1=CC=C(Cl)C(NC(=O)NC2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=C1 Chemical compound COC1=CC=C(Cl)C(NC(=O)NC2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=C1 NVOHUTVLFUTBHX-UHFFFAOYSA-N 0.000 description 1
- JEDUXCVVPNEFCQ-UHFFFAOYSA-N COC1=CC=C(Cl)C(NC(=O)NC2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=C1Cl Chemical compound COC1=CC=C(Cl)C(NC(=O)NC2=NC=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=C2)=C1Cl JEDUXCVVPNEFCQ-UHFFFAOYSA-N 0.000 description 1
- 102220538340 CST complex subunit STN1_S248C_mutation Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 206010049889 Craniosynostosis Diseases 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102300050818 Fibroblast growth factor receptor 3 isoform 1 Human genes 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101000917148 Homo sapiens Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010061274 Malocclusion Diseases 0.000 description 1
- 101100334739 Mus musculus Fgfr3 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- INJFZZQMUGZOOW-UHFFFAOYSA-N O=C=O.[H]CCN1C=C(CNC2=NC=C3C=C(C4=CC(OC)=CC(OC)=C4)C(NC(=O)NC(C)(C)C)=NC3=N2)N=N1 Chemical compound O=C=O.[H]CCN1C=C(CNC2=NC=C3C=C(C4=CC(OC)=CC(OC)=C4)C(NC(=O)NC(C)(C)C)=NC3=N2)N=N1 INJFZZQMUGZOOW-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000055251 Proto-Oncogene Proteins c-cbl Human genes 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WRUAHXANJKHFIL-UHFFFAOYSA-N benzene-1,3-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC(S(O)(=O)=O)=C1 WRUAHXANJKHFIL-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000002884 conformational search Methods 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 210000004714 cranial suture Anatomy 0.000 description 1
- 230000008226 craniofacial development Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 210000003275 diaphysis Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000009643 growth defect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 102000055709 human FGFR3 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000003559 hypertrophic chondrocyte Anatomy 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102200000811 rs121912608 Human genes 0.000 description 1
- 102200143266 rs121913483 Human genes 0.000 description 1
- 102200154849 rs12449580 Human genes 0.000 description 1
- 102220014664 rs139709036 Human genes 0.000 description 1
- 102200143279 rs28931615 Human genes 0.000 description 1
- 102220024095 rs587778776 Human genes 0.000 description 1
- 102220124153 rs886043613 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/001—Combinations of extrusion moulding with other shaping operations
- B29C48/0017—Combinations of extrusion moulding with other shaping operations combined with blow-moulding or thermoforming
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/022—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the choice of material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/30—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers
- B32B27/302—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers comprising aromatic vinyl (co)polymers, e.g. styrenic (co)polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/18—Manufacture of films or sheets
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L25/00—Compositions of, homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Compositions of derivatives of such polymers
- C08L25/02—Homopolymers or copolymers of hydrocarbons
- C08L25/04—Homopolymers or copolymers of styrene
- C08L25/06—Polystyrene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L51/00—Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
- C08L51/04—Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers grafted on to rubbers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2025/00—Use of polymers of vinyl-aromatic compounds or derivatives thereof as moulding material
- B29K2025/04—Polymers of styrene
- B29K2025/06—PS, i.e. polystyrene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2035/00—Use of polymers of unsaturated polycarboxylic acids or derivatives thereof as moulding material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2201/00—Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as reinforcement
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/712—Containers; Packaging elements or accessories, Packages
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2262/00—Composition or structural features of fibres which form a fibrous or filamentary layer or are present as additives
- B32B2262/06—Vegetal fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2270/00—Resin or rubber layer containing a blend of at least two different polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2439/00—Containers; Receptacles
- B32B2439/70—Food packaging
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2325/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Derivatives of such polymers
- C08J2325/02—Homopolymers or copolymers of hydrocarbons
- C08J2325/04—Homopolymers or copolymers of styrene
- C08J2325/06—Polystyrene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2401/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2401/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
- C08J2401/02—Cellulose; Modified cellulose
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2425/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Derivatives of such polymers
- C08J2425/02—Homopolymers or copolymers of hydrocarbons
- C08J2425/04—Homopolymers or copolymers of styrene
- C08J2425/06—Polystyrene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2425/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Derivatives of such polymers
- C08J2425/02—Homopolymers or copolymers of hydrocarbons
- C08J2425/04—Homopolymers or copolymers of styrene
- C08J2425/08—Copolymers of styrene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2447/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds; Derivatives of such polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/30—Applications used for thermoforming
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
- C08L2205/025—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group containing two or more polymers of the same hierarchy C08L, and differing only in parameters such as density, comonomer content, molecular weight, structure
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/03—Polymer mixtures characterised by other features containing three or more polymers in a blend
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/03—Polymer mixtures characterised by other features containing three or more polymers in a blend
- C08L2205/035—Polymer mixtures characterised by other features containing three or more polymers in a blend containing four or more polymers in a blend
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/14—Polymer mixtures characterised by other features containing polymeric additives characterised by shape
- C08L2205/16—Fibres; Fibrils
Abstract
Description
- The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases and craniosynostosis, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
- Skeletal development in humans is regulated by numerous growth factors. Among them Fibroblast Growth Factor Receptor 3 (FGFR3) has been described as both a negative and a positive regulator of endochondral ossification.
- The FGFR3 gene, which is located on the distal short arm of chromosome 4, encodes a 806 amino acid protein precursor (fibroblast growth factor receptor 3
isoform 1 precursor; SEQ ID NO: 1). - The FGFR3 protein belongs to the receptor-tyrosine kinase family. This family comprises receptors FGFR1, FGFR2, FGFR3 and FGFR4 that respond to fibroblast growth factor (FGF) ligands. These structurally related proteins exhibit an extracellular domain composed of three immunoglobin-like domains which form the ligand-binding domain, an acid box, a single transmembrane domain and an intracellular split tyrosine kinase domain. Although to date the physiological ligand(s) for FGFR3 is (are) not known, like other FGFRs, it is activated by FGF ligands. Binding of one of the 22 FGFs induces receptor dimerization and autophosphorylation of tyrosine residues in the cytoplasmic domain. The phosphorylated tyrosine residues are required for activation of the signaling pathways. The most relevant tyrosines are Y648, Y647, located in the activation loop.
- Several signaling pathways have been described downstream of FGFR3 activation, including the ERK and p38 MAP kinase pathways (Legeai-Mallet et al., J Biol Chem, 273: 13007-13014, 1998; Murakami et al., Genes Dev, 18: 290-305, 2004; Matsushita et al., Hum Mol Genet, 18: 227-240, 2009; Krejci at al., J Cell Sci, 121: 272-281, 2008) and the signal transducer and activation of transcription (STAT) pathway (Su, W. C. et al., Nature, 386: 288-292, 1997; Legeai-Mallet et al., Bone, 34: 26-3, 2004; Li, C. et al., Hum Mol Genet, 8: 35-44, 1999). Others pathways in endochondral bone growth have been identified such as the phosphoinositide 3 kinase-AKT (Ulici, V. et al., Bone, 45: 1133-1145, 2009) and protein kinase C pathways. The degradation of mutant receptors is disturbed as demonstrated by higher levels of FGFR3 mutant receptors at the cell surface (Monsonego-Oman et al., Mol Cell Biol, 20: 516-522, 2000; Monsonego-Oman et al., FEBS Lett, 528: 83-89, 2002; Delezoide et al., Hum Mol Genet, 6: 1899-1906, 1997), and disruption of c-Cbl-mediated ubiquitination (Cho, J. Y. et al., Proc Natl Acad Sci USA, 101: 609-614, 2004). FGFR3 mutations disrupt the formation of glycosylated isoforms of the receptor and impeded its trafficking (Gibbs at al., Biochim Biophys Acta, 1773: 502-512, 2007; Bonaventure et al., FEBS J, 274: 3078-3093, 2007).
- While long bone development involves endochondral ossification, craniofacial development is dependent on both endochondral and membranous ossification.
- In skull vault, activated FGFR3 induces craniosiosynostosis. This disease consists of premature fusion of one or more of the cranial sutures. Two FGFR3 mutations cause specific craniosynostoses, Muenke syndrome and Crouzon syndrome with acanthosis nigricans. These diseases are an autosomal dominant hereditary disorder.
- In long bone, FGFR3, when activated, exerts a negative regulatory influence mainly in the growth phase, in which it reduces the turnover necessary for bone elongation, the rate of cartilage template formation and disrupts chondrocyte proliferation and differentiation.
- Abnormal FGFR3 overactivation or constitutive activation of FGFR3 leads to a severe disorganization of the growth plate cartilage. Gain of function mutants of FGFR3 (also called “constitutively active mutants of FGFR3”) disrupt endochondral ossification in a spectrum of skeletal dysplasias which include achondroplasia (ACH), the most common form of human dwarfism, hypochondroplasia (HCH), and thanatophoric dysplasia (TD), the most common form of lethal skeletal dysplasia. On the contrary, it has been shown that FGFR3 knock-out mice and humans without functional FGFR3 demonstrate skeletal overgrowth.
- Therefore, FGFR3-related skeletal diseases (e.g. FGFR3-related skeletal dysplasias and FGFR3-related craniosiosynostosis) are the result of increased signal transduction from the activated receptor.
- Among skeletal dysplasias, achondroplasia is of particular interest since it is one of the most common congenital diseases responsible for dwarfism, disorder characterized by short limbs relative to trunk. It is diagnosed by growth failure in the major axes of the long bones of extremities and typical physical features such as a large frontally projecting cranium and a short nose. This disease is an autosomal dominant hereditary disorder, but most of cases are found to be sporadic. Hypochondroplasia is also characterized by short stature with disproportionately short arms and legs. The skeletal features are very similar to achondroplasia but usually tend to be milder.
- Current therapies of achondroplasia and hypochondroplasia include orthopedic surgeries such as leg lengthening and growth hormone therapy. However, leg lengthening inflicts a great pain on patients, and growth hormone therapy increases body height by means of periodic growth hormone injections starting from childhood. Further, growth ceases when injections are stopped.
- Consequently, it is desirable to develop a new achondroplasia and hypochondroplasia therapy and to identify molecules suitable for treating achondroplasia and hypochondroplasia, as well as other FGFR3-related skeletal diseases such as FGFR3-related craniosiosynostosis.
- In an attempt to find a new treatment for skeletal diseases, the inventors succeeded in restoring bone growth by administering tyrosine kinase inhibitors, more particularly inhibitors which are able to inhibit auto-phosphorylation of FGFR3. Indeed, the inventors have shown in an ex vivo model (consisting of culturing femurs of embryonic dwarf mice which displays impaired endochondral ossification) that tyrosine kinase inhibitors (in particular those which prevent ATP from binding to the “ATP binding site” of FGFR3) restore a normal growth of the bones. Further, the inventors have shown in vivo in an animal model that administration of tyrosine kinase inhibitors (e.g. compounds that belong to the pyrido[2,3-d]pyrimidine class and to the N-aryl-N′-pyrimidin-4-yl urea class) improves dwarfism condition by increasing growth of bones.
- Consequently, inhibitors of FGFR3 are useful for treating FGFR3-related skeletal diseases.
- Therefore, the present invention provides a method for treating or preventing FGFR3-related skeletal diseases which comprises the step of administering at least one antagonist of the FGFR3 tyrosine kinase receptor, or a composition comprising such an antagonist, to a subject in need thereof.
- The invention also relates to an antagonist of the FGFR3, or a composition comprising such an antagonist, for use in the treatment or prevention of FGFR3-related skeletal diseases.
- As used herein, the terms “FGFR3”, “FGFR3 tyrosine kinase receptor” and “FGFR3 receptor” are used interchangeably throughout the specification and refer to all of the naturally-occurring isoforms of FGFR3.
- In particular, an antagonist of a FGFR3 tyrosine kinase receptor refers to an antagonist capable of inhibiting or blocking the activity of:
-
- a) a FGFR3 polypeptide comprising or consisting of the amino acid sequence shown in NCBI reference NP_000133 and in UniProt reference P22607 (sequence SEQ ID NO: 1); and/or
- b) a FGFR3 corresponding to the mature isoform of the a FGFR3 polypeptide of (a) (i.e. obtained after cleavage of the signal peptide); and/or
- c) an allelic variant of a FGFR3 of (a) or (b); and/or
- d) a splice variant of a FGFR3 of (a), (b) or (c); and/or
- e) a constitutively active mutant of a FGFR3 of (a), (b), (c) or (d).
- f) an isoform obtained by proteolytic processing of a FGFR3 of (a), (b), (c), (d) or (e).
- As used herein, the expressions “constitutively active FGFR3 receptor variant”, “constitutively active mutant of the FGFR3” or “mutant FGFR3 dissolving a constitutive activity” are used interchangeably and refer to a mutant of said receptor exhibiting a biological activity (i.e. triggering downstream signaling) in the absence of FGF ligand stimulation, and/or exhibiting a biological activity which is higher than the biological activity of the corresponding wild-type receptor in the presence of FGF ligand.
- A constitutively active FGFR3 variant according to the invention is in particular chosen from the group consisting of (residues are numbered according to their position in the precursor of fibroblast growth factor receptor 3 isoform 1-806 amino acids long-):
-
- a mutant wherein the serine residue at position 84 is substituted with lysine (named herein below S84L);
- a mutant wherein the arginine residue at position 248 is substituted with cysteine (named herein below R200C);
- a mutant wherein the arginine residue at position 248 is substituted with cysteine (named herein below R248C);
- a mutant wherein the serine residue at position 249 is substituted with cysteine (named herein below S249C);
- a mutant wherein the proline residue at position 250 is substituted with arginine (named herein below P250R);
- a mutant wherein the asparagine residue at position 262 is substituted with histidine (named herein below N262H);
- a mutant wherein the glycine residue at position 268 is substituted with cysteine (named herein below G268C);
- a mutant wherein the tyrosine residue at position 278 is substituted with cysteine (named herein below Y278C)
- a mutant wherein the serine residue at position 279 is substituted with cysteine (named herein below S279C);
- a mutant wherein the glycine residue at position 370 is substituted with cysteine (named herein below G370C);
- a mutant wherein the serine residue at position 371 is substituted with cysteine (named herein below S371C);
- a mutant wherein the tyrosine residue at position 373 is substituted with cysteine (named herein below Y373C);
- a mutant wherein the glycine residue at position 380 is substituted with arginine (named herein below G380R);
- a mutant wherein the valine residue at position 381 is substituted with glutamate (named herein below V381E);
- a mutant wherein the alanine residue at position 391 is substituted with glutamate (named herein below A391E);
- a mutant wherein the asparagine residue at position 540 is substituted with Lysine (named herein below N540K);
- a mutant wherein the termination codon is eliminated due to base substitutions, in particular the mutant wherein the termination codon is mutated in an arginine, cysteine, glycine, serine or tryptophane codon (named herein below X807R, X807C, X807G, X807S and X807W, respectively);
- a mutant wherein the lysine residue at position 650 is substituted with another residue, in particular with methionine, glutamate, asparagine or glutamine (named herein below K650M, K650E, K650N and K650Q).
- Preferably, a constitutively active FGFR3 variant according to the invention is K650M, K650E or Y373C mutant.
- In the context of the present invention, the term “FGFR3-related skeletal disease” is intended to mean a skeletal disease that is caused by an abnormal increased activation of FGFR3, in particular by expression of a constitutively active mutant of the FGFR3 receptor, in particular a constitutively active mutant of the FGFR3 receptor as described above.
- The FGFR3-related skeletal diseases are preferably FGFR3-related skeletal dysplasias and FGFR3-related craniosynostosis.
- The FGFR3-related skeletal dysplasias according to the invention may correspond to an inherited or to a sporadic disease.
- As used herein, the term “FGFR3-related skeletal dysplasias” includes but is not limited to thanatophoric dysplasia type I, thanatophoric dysplasia type II, hypochondroplasia, achondroplasia and SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans).
- In a preferred embodiment, the FGFR3-related skeletal dysplasia is caused by expression in the subject of a constitutively active FGFR3 receptor variant such as defined above.
- In a preferred embodiment, the FGFR3-related skeletal dysplasia is a achondroplasia caused by expression of the G380R constitutively active mutant of the FGFR3 receptor.
- In a preferred embodiment, the FGFR3-related skeletal dysplasia is a hypochondroplasia caused by expression of the N540K, K650N, K650Q, S84L, R200C, N262H, G268C, Y278C, S279C, V381E, constitutively active mutant of the FGFR3 receptor.
- In a preferred embodiment, the FGFR3-related skeletal dysplasia is a thanatophoric dysplasia type I caused by expression of a constitutively active mutant of the FGFR3 receptor chosen from the group consisting of R248C, S248C, G370C, S371C; Y373C, X807R, X807C, X807G, X807S, X807W and K650M FGFR3 receptors.
- In a preferred embodiment, the FGFR3-related skeletal dysplasia is a thanatophoric dysplasia type II caused by expression of the K650E constitutively active mutant of the FGFR3 receptor.
- In a preferred embodiment, the FGFR3-related skeletal dysplasia is a severe severe achondroplasia with developmental delay and acanthosis nigricans caused by expression of the K650M constitutively active mutant of the FGFR3 receptor
- The FGFR3-related craniosynostosis according to the invention may correspond to an inherited or to a sporadic disease.
- In a preferred embodiment, the FGFR3-related craniosynostosis is Muenke syndrome caused by expression of the P250R constitutively active mutant of the FGFR3 receptor or Crouzon syndrome with acanthosis nigricans caused by expression of the A391G constitutively active mutant of the FGFR3 receptor.
- As used herein the term “antagonist” refers to an agent (i.e. a molecule) which inhibits or blocks the activity of FGFR3. For instance, an antagonist of FGFR3 refers to a molecule which inhibits or blocks the activity of the FGFR3 receptor. Preferably, the FGFR3 antagonists according to the invention act through direct interaction with the FGFR3 receptor.
- The antagonists of the present invention act by blocking or reducing FGFR3 receptor functional activation. This may for example be achieved by interfering with FGF ligand binding to FGFR3 receptor or with ATP binding to “ATP binding site” of FGFR3 receptor for preventing phosphorylation of tyrosine residues located towards the cytoplasmic domain (activation loop), i.e. on Tyr648 and Tyr547.
- Alternatively, this may be achieved by reducing or preventing expression of FGFR3 receptor.
- The term “expression” when used in the context of expression of a gene or nucleic acid refers to the conversion of the information, contained in a gene, into a gene product. A gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA or any other type of RNA) or a protein (i.e. FGFR3) produced by translation of a mRNA.
- Both options ultimately result in blocking or reducing signal transduction, hence in blocking or reducing receptors functional activity.
- The antagonists according to the invention are capable of inhibiting or eliminating the functional activation of the FGFR3 receptor in vivo and/or in vitro. The antagonist may inhibit the functional activation of the FGFR3 receptor by at least about 10%, preferably by at least about 30%, preferably by at least about 50%, preferably by at least about 70, 75 or 80%, still preferably by 85, 90, 95, or 100%.
- Preferably, the antagonists according to the invention are more specific for FGFR3 versus FGFR1, 2 and 4, for instance the inhibitor constant “KI” of the antagonists for FGFR3 is at least 2, preferably 5, more preferably 10, times lower than the KI for at least one of FGFR1, 2 and 4.
- Antagonists for FGFR3 receptor are well-known to those skilled in the art and include, e.g., anti-FGFR3 antibodies, for instance the antibodies described by Rauchenberger, R. et al. (J. Biol. Chem. 2003 Oct. 3; 278(40):38194-205.), Martinez-Torrecuadrada, J., et al. (Clin. Cancer Res. 2005 Sep. 1; 11(17):6280-90), Trudel S., et al., (Blood 2006 May 15; 107(10):4039-46.), Qing J. et al. (J. Clin. Invest. 2009, 119(5):1216-29), the anti-FGFR3 antibodies disclosed in IN2011CN02023, WO2010/111367, US 2010/0098696, WO2010/02862, WO2007/144893, WO2002/102973.
- Antagonists for FGFR3 receptor also include small chemical molecules, for instance those disclosed in WO2010/22169 (e.g. the compound of
general formula 1 corresponding to 4,4′,4″,4′″-[carbonyl-bis[imino-5, 1,3-benzenetriyl bis-{carbonylimino}]3tetrakis-{benzene-1,3-disulfonic acid}), WO2007/26251, WO2005/47244, US2005/261307, as well as nucleic acid compounds for regulating/inhibiting FGFR3 expression described in WO2003/23004, US2007/049545 and WO2011/139843. - Functional activation of the FGFR3 receptor may be readily assessed by the one skilled in the art according to known methods. Indeed, since activated FGFR3 receptor is phosphorylated on tyrosine residues located towards the cytoplasmic domain, i.e. on Tyr648 and Tyr647, functional activation of the FGFR3 receptor may for example be assessed by measuring its phosphorylation.
- For instance, analysis of ligand-induced phosphorylation of the FGFR3 receptor can be preformed as described in Le Corre et al. (Org. Biomol. Chem., 8: 2164-2173, 2010).
- Alternatively, receptor phosphorylation in cells can be readily detected by immunocytochemistry, immunohistochemistry and/or flow cytometry using antibodies which specifically recognize this modification. For instance phosphorylation of FGFR3 on the Tyr648 and Tyr647 residues can be detected by immunocytochemistry, immunohistochemistry and/or flow cytometry using monoclonal or polyclonal antibodies directed against phosphorylated Tyr648 and Tyr647-FGFR3.
- Functional activation of the FGFR3 receptor may also be tested by using FGFR3-dependent cell lines (for instance BaF3 cell line). The FGFR3 antagonist activity of a compound is determined by measuring its ability to inhibit the proliferation of a FGFR3-dependent cell line (see methods described by Vito Guagnano et al., Journal of Medicinal Chemistry, 54: 7066-7083, 2011).
- Further, FGFR3, when associated with its ligand, mediates signaling by activating the ERK and p38 MAP kinase pathways, and the STAT pathway. Therefore activation of FGFR3 receptor can also be assessed by determining the activation of these specific pathways as described by Horton et al. (lancet, 370: 162-172, 2007)
- Accordingly, an antagonist may be identified as a molecule which reduces the level of phosphorylation of the receptor to be tested upon stimulation with its specific ligand of a cell expressing said receptor, as compared with the level of receptor phosphorylation measured in the cell when stimulated with its specific ligand in the absence of the antagonist.
- The antagonists according to the present invention include those which specifically bind to the FGFR3 receptor, thereby reducing or blocking signal transduction. Antagonists of this type include antibodies (in particular the antibodies as disclosed above) or aptamers which bind to FGFR3, fusion polypeptides, peptides, small chemical molecules which bind to FGFR3, and peptidomimetics.
- The term “small chemical molecule” refers to a molecule, preferably of less than 1,000 daltons, in particular organic or inorganic compounds. Structural design in chemistry should help to find such a molecule.
- According to a preferred embodiment, the small chemical molecule prevents binding of ATP to the “ATP binding site” of FGFR3. In a more preferred embodiment, the small chemical molecule which prevents binding of ATP to the “ATP binding site” of FGFR3 belongs to the pyrido[2,3-d]pyrimidine class.
- More preferably, the small chemical molecule which prevents binding of ATP to the “ATP binding site” of FGFR3 is selected from the group consisting of the compounds PD173074, 18, 19a to 19 m, 22b, 22c, 23b to 23f disclosed in table below (as well as in
FIG. 2a and Scheme 3 of the article by Le Corre et al., Org. Biomol. Chem., 8: 2164-2173, 2010). - Advantageously, the small chemical molecule which prevents binding of ATP to the “ATP binding site” of FGFR3 is the compound PD173075 or the compound 19g, corresponding to compound “A31” disclosed in
FIG. 1A of the present application and in Table A. - In another more preferred embodiment, the small chemical molecule which prevents binding of ATP to the “ATP binding site” of FGFR3 belongs to the N-aryl-N′-pyrimidin-4-yl urea class.
- More preferably, the small chemical molecule which prevents binding of ATP to the “ATP binding site” of FGFR3 is selected from the group consisting of the compounds 1a to in disclosed in Table B below (as well as in Table 1 of the article by Vito Guagnano et al., Journal of Medicinal Chemistry, 54: 7066-7083, 2011).
- Advantageously, the small chemical molecule which prevents binding of ATP to the “ATP binding site” of FGFR3 is the compound 1h (also named BGJ-398), disclosed in the Table B below.
- As used herein the term “polypeptide” refers to any chain of amino acids linked by peptide bonds, regardless of length or post-translational modification. Polypeptides include natural proteins, synthetic or recombinant polypeptides and peptides (i.e. polypeptides of less than 50 amino acids) as well as hybrid, post-translationally modified polypeptides, and peptidomimetic.
- As used herein, the term “amino acid” refers to the 20 standard alpha-amino acids as well as naturally occurring and synthetic derivatives. A polypeptide may contain L or D amino acids or a combination thereof.
- As used herein the term “peptidomimetic” refers to peptide-like structures which have non-amino acid structures substituted but which mimic the chemical structure of a peptide.
- The term “antibody” refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. As such, the term antibody encompasses not only whole antibody molecules, but also antibody fragments as well as variants (including derivatives) of antibodies and antibody fragments.
- In particular, the antibody according to the invention may correspond to a polyclonal antibody, a monoclonal antibody (e.g. a chimeric, humanized or human antibody), a fragment of a polyclonal or monoclonal antibody or a diabody.
- “Antibody fragments” comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fv, Fab, F(ab′)2, Fab′, Fd, dAb, dsFv, scFv, sc(Fv)2, CDRs, diabodies and multi-specific antibodies formed from antibodies fragments.
- Antibodies according to the invention may be produced by any technique known in the art, such as, without limitation, any chemical, biological, genetic or enzymatic technique, either alone or in combination. The antibodies of this invention can be obtained by producing and culturing hybridomas.
- According to a preferred embodiment, the antagonist is an antibody which specifically recognizes and binds to the FGFR3 receptor and prevents binding of ATP to the ATP binding site of FGFR3.
- In another embodiment, the antagonist is an antibody which prevents functional oligomerization of the receptor.
- “Aptamers” are a class of molecule that represents an alternative to antibodies in term of molecular recognition. Aptamers are oligonucleotide or oligopeptide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity. Such ligands may be isolated through Systematic Evolution of Ligands by EXponential enrichment (SELEX) of a random sequence library, as described in Tuerk C. and Gold L., Science, 1990, 249(4968):505-10. The random sequence library is obtainable by combinatorial chemical synthesis of DNA. In this library, each member is a linear oligomer, eventually chemically modified, of a unique sequence. Possible modifications, uses and advantages of this class of molecules have been reviewed in Jayasena S. D., Clin. Chem., 1999, 45(9):1628-50. Peptide aptamers consists of a conformationally constrained antibody variable region displayed by a platform protein, such as E. coli Thioredoxin A that are selected from combinatorial libraries by two hybrid methods (Colas et al., Nature, 1996, 380, 548-50).
- In order to target the antagonist of the invention specifically to growth plate chondrocytes, the antagonist may be tagged with molecules that possess affinity for cartilage or chondrocytes. Such molecules are for instance described by Rothenfluh et al. (Nat Mater 7: 248-254, 2008), and Laroui H et al. (Biomacromolecules, 8: 1041-1021, 2007).
- The antagonist of the invention can be used in combination with growth hormones and/or substances activating guanylyl cyclase B (such as the substances disclosed in application US 2003/0068313).
- The antagonists comprises in the combination are intended to be administered simultaneously or sequentially.
- Thus, the present invention also relates to a combination of at least one antagonist of the invention and at least one other agent such as growth hormones and/or substances activating guanylyl cyclase B, for sequential or simultaneous use in the treatment or prevention of a FGFR3-related skeletal dysplasia.
- The antagonist or combination used in the above recited method or use are provided in a pharmaceutically acceptable carrier, exipient or diluent which is not prejudicial to the patient to be treated.
- Pharmaceutically acceptable carriers and exipient that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminium stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-a-
tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. - As appreciated by skilled artisans, compositions are suitably formulated to be compatible with the intended route of administration. Examples of suitable routes of administration include parenteral route, including for instance intramuscular, subcutaneous, intravenous, intraperitoneal or local intratumoral injections. The oral route can also be used, provided that the composition is in a form suitable for oral administration, able to protect the active principle from the gastric and intestinal enzymes.
- Further, the amount of antagonist or combination used in the above recited method or use is a therapeutically effective amount. A therapeutically effective amount of antagonist is that amount sufficient to achieve growth of bones or cartilages, or to treat a desired disease without causing overly negative effects in the subject to which the antagonist or the combination is administered. The exact amount of antagonist to be used and the composition to be administered will vary according to the age and the weight of the patient being treated, the type of disease, the mode of administration, the frequency of administration as well as the other ingredients in the composition which comprises the antagonist. Generally, the antagonist for use in the treatment or prevention of FGFR3-related skeletal dysplasias may be administered in the rage from about 100 μg/kg to 1 mg/kg, alternatively from about 1 mg to about 10 mg/Kg, alternatively from about 10 mg to about 100 mg/Kg. Effective doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents.
- When the antagonist belongs to the pyrido[2,3-d]pyrimidine class, it is preferably administered in the range from about 1 mg/kg to about 10 mg/Kg. Typically, antagonist PD173074 is administered from about 1 mg/kg to about 10 mg/Kg, preferably from 2 mg/kg to about 8 mg/Kg, more preferably 4 mg/kg to about 6 mg/Kg. When the antagonist belongs to the N-aryl-N′-pyrimidin-4-yl urea class, it is preferably administered in the range from about 1 mg/kg to about 10 mg/Kg. Typically, antagonist BGJ-398 is administered from about 1 mg/kg to about 10 mg/Kg, preferably from 2 mg/kg to about 8 mg/Kg, more preferably 4 mg/kg to about 6 mg/Kg. Advantageously, BGJ-398 is administered to 1.66 mg/kg.
- As used herein, the term “subject” denotes a human or non-human mammal, such as a rodent, a feline, a canine, or a primate. Preferably, the subject is a human being, more preferably a child (i.e. a child who is growing up). Preferably, when the subject to be treated is a child, the antagonist is administered during all or part of child growth period.
- In the context of the invention, the term “treating” is used herein to characterize a therapeutic method or process that is aimed at (1) slowing down or stopping the progression, aggravation, or deterioration of the symptoms of the disease state or condition to which such term applies; (2) alleviating or bringing about ameliorations of the symptoms of the disease state or condition to which such term applies; and/or (3) reversing or curing the disease state or condition to which such term applies.
- As used herein, the term “preventing” intends characterizing a prophylactic method or process that is aimed at delaying or preventing the onset of a disorder or condition to which such term applies.
- Throughout the present application, the references to entries of public databases refer to the entries in force on Nov. 23, 2011. Further, throughout this application, various references are cited. The disclosures of these references are hereby incorporated by reference into the present disclosure.
- The present invention will be further illustrated by the additional description which follows, which refer to examples which show that administration tyrosine kinase inhibitors, in particular a compound which belong to the pyrido[2,3-d]pyrimidine class or to the N-aryl-N′-pyrimidin-4-yl urea class, restores bone growth in ex vivo and in vivo models. It should be understood however that the invention is defined by the claims, and that these examples are given only by way of illustration of the invention and do not constitute in anyway a limitation thereof.
-
FIG. 1 . A31 prevents the kinase activity of FGFR3. - (A) Molecular scheme of the A31 compound. (B) Overall structure showing docking conformation of A31 inside the FGFR3 binding pocket. A31 is represented with rods. (C) Overall structure showing A31 in the ATP binding site.
-
FIG. 2 . A31 inhibits the constitutive activation of FGFR3. - Immunoblots showing FGFR3 overexpression in transfected cells (HEK) with WT human-cDNA (FGFR3+/+) and 3 human mutant cDNA constructs (FGFR3Y373C, FGFR3K650E, FGFR3K650M). FGFR3 is immunoprecipitated (IP) and immunoblotted (IB) with anti-FGFR3 and antiphosphotyrosine antibodies (Ptyr). Ptyr immunoblot showing constitutive phosphorylation of FGFR3 in transfected cells with mutant cDNA constructs. FGFR3 immunoblots showing three isoforms of the protein (105, 115 and 130 kDa) in WT (FGFR3+/+) and one mutant (FGFR3Y373C/+). Two isoforms of FGFR3 protein (105 kDa and 115 kDa) were present in cells transfected with mutant constructs (FGFR3K650M and FGFR3K650E). A31 reduces the constitutive phosphorylation of FGFR3.
-
FIG. 3 . A31 restores longitudinal bone growth of Fgfr3Y367C/+ femurs. - (A) Fgfr3Y367C/+ mouse embryo at E16.5 shows a dome-shape skull. (B) Fgfr3Y367C/+ femur is broader with a shorter diaphysis at E16.5 (C) Alizarin red and alcian blue staining show the small size of Fgfr3Y367C/+ femurs. A31 increases the size of the Fgfr3Y367C/+ femurs after 5 days of culture. (D) Bone length measurements showing a reduced longitudinal growth in Fgfr3Y367C/+ femurs compared with WT (Fgfr3Y367C/+, 461±119 μm; WT, 1247±227 μm; p<10−10). A31 enhances longitudinal growth in Fgfr3Y367C/+ femurs, the bone growth is greater in Fgfr3Y367C/+ femurs compared with controls (Fgfr3Y367C/+, 1880±558 μm; WT, 1863±255 μm; ***p<10−19 versus untreated controls). The experiments were performed 6 times and bone length is shown as mean+/−s.d.
-
FIG. 4 . A31 modifies the size of the growth plate and chondrocyte morphology. - (A) HES staining showing the reduced size of the Fgfr3Y367C/+ growth plate. A31 induces an increase in the size of the growth plate of the Fgfr3Y367C/+ mice. (B) In situ hybridization of type X collagen showing a markedly reduced hypertrophic zone (see the size of “H” symbolized by the size of the double-headed arrows) of Fgfr3Y367C/+ growth plates compared with WT. A31 induces enhanced type X collagen expression in Fgfr3Y367C/+ growth plates.
-
FIG. 5 . A31 decreases Fgfr3 overexpression in Fgfr3Y367C/+ femurs. - Costal primary chondrocytes were examined by western-blot with anti-FGFR3. Fgfr3 protein level is higher in Fgfr3Y367C/+ chondrocytes compared with WT. A31 reduced this overexpression.
-
FIG. 6 . A31 reduces proliferation and cell cycle regulator expression in growth plates. - (A) Quantification of PCNA-positive cells in proliferative (P), prehypertrophic (PH) and hypertrophic zones (H) showing a higher level of PCNA positive cells in Fgfr3Y367C/+ growth plates (73% (PH) and 43% (H), **p<0.005 versus WT) compared with WT (31% (PH) and 18% (H)). A31 induces a strong decrease of PCNA expression in PH and H zones of Fgfr3Y367C/+ growth plates (20% (PH) and 18% (H), ***p<10-4 versus untreated femurs). The experiments were performed six times and three observers counted positive cells. % PCNA positive cells are shown as mean+/−s.d. (B) Immunoblot showing a higher cyclin D1 expression in costal primary Fgfr3Y367C/+ chondrocytes compared with WT. A31 reduces the expression of cyclin D1 in Fgfr3Y367C/+ chondrocytes. Actin is included as loading control.
-
FIG. 7 . PD173074 restores longitudinal bone growth of Fgfr3Y367C/+ femurs. - (A) Alizarin red and alcian blue staining show that after 5 days of culture PD173074 increases the size of the Fgfr3Y367C/+ femurs (left panel). The effect of PD173074 on femur growth is similar to that of A31 (right panel).
- (B) PD173074 enhances longitudinal growth in Fgfr3Y367C/+ femurs (see bar “PD173074” vs bar “no treatment”), and the bone growth of PD173074 treated femurs is analogous to that observed when Fgfr3Y367C/+ femurs are treated with A31.
-
FIG. 8 . PD173074 attenuates the dwarfism phenotype of Fgfr3Y367C/+ mice. - Fgfr3Y367C/+ mice seven days old received daily subcutaneous administration of 4.00 mg/kg PD173074 for 10 days. Effect of the treatment on the skeleton and body growth was assessed by an X-rays analysis. On panels (A) and (B), PD173074 treated Fgfr3Y367C/+ mouse is on the left, vehicle treated Fgfr3Y367C/+ mouse is on the right).
-
FIG. 9 . BGJ-398 restores longitudinal bone growth of Fgfr3Y367C/+ femurs. - Bone length measurements showing a reduced longitudinal growth in Fgfr3Y367C/+ femurs compared with WT (Fgfr3+/+). Concentration of BGJ-398 ranging from 100 nM to 1 μM enhances longitudinal growth in Fgfr3Y367C/+ femurs: the bone growth is greater in Fgfr3Y367C/+ femurs compared with controls (Fgfr3+/+).
-
FIG. 10 . BGJ-398 modifies the size of the growth plate and chondrocyte morphology. - (A) HES staining showing the reduced size of the Fgfr3Y367C/+ growth plate. BGJ-398 induces an increase in the size of the growth plate of the Fgfr3Y367C/+ mice. (B) In situ hybridization of type X collagen showing a markedly reduced hypertrophic zone (symbolized by the size of the double-headed arrows) of Fgfr3Y367C/+ growth plates compared with WT (Fgfr3+/+). BGJ-398 induces enhanced type X collagen expression in Fgfr3Y367C/+ growth plates.
-
FIG. 11 . BGJ-398 attenuates the dwarfism phenotype of Fgfr3Y367C/+ mice. - Fgfr3Y367C/+ mice seven days old received daily subcutaneous administration of 1.66 mg/kg BGJ-398 for 10 days. Effect of the treatment on the skeleton and body growth was assessed by an X-rays analysis (BGJ-398 treated Fgfr3Y367C/+ mouse is on the left, vehicle treated Fgfr3Y367C/+ mouse is on the right).
- Chemical Compound.
- A series of inhibitors was previously designed and synthesized as PD173074 (Miyake at al., J Pharmacol Exp Rher., 332: 797-802, 2010) analogues bearing various N-substituents. Of 27 analogues synthesized, A31 (refers to 19g) was selected in the course of preliminary cellular assays for its ability to inhibit FGFR3 phosphorylation (Le Corre at al., Org Biomol Chem, 8: 2164-2173, 2010.). This compound competes with ATP binding and can inhibit autophosphorylation of FGFR3, with an IC50 value of approximately 190 nM. As a control, the inventors used the commercial FGFR TKI, PD173074. TKIs were dissolved in dimethyl sulfoxide (DMSO) at a concentration of 10 mM. The stock solution was stored at −20° C. before use.
- Computational Analyses.
- The kinase domain structure of FGFR3 was predicted by homology modelling with the Esypred3D software (Lambert et al., Bioinformatics, 18: 1250-1256, 2002) using a recent X-ray structure of the highly homologous FGFR1 protein (pdb code 3JS2) (Ravindranathan at al., J Med Chem, 53: 1662-1672, 2010). The inventors used AMBER software (Case, D. A., Darden, T. A., Cheatham, T. E., Simmerling, C. L., Wang, J., Duke, R. E., Luo, R., Merz, K. M., Pearlman, D. A., Crowley, M. et al. (2006). University of California, San Francisco) according to a previously published protocol (Luo, Y. et al., J Mol Model, 14: 901-910, 2008). The inventors built A31 compound using the Sybyl software package version 11.0 (SYBYL. Tripos Inc., 1699 South Hanley Rd., St Louis, Mo., 63144 USA). Two states of the asymmetric carbon (R, S) and two different protonation states of the neighboring amino moiety (neutral and +1) were considered. Four distinct chemical structures were obtained. Energy minimizations of these four A31 structures were performed (Hu, R., Barbault, F., Delamar, M. and Zhang, R., Bioorg Med Chem, 17: 2400-2409, 2009). Docking calculations were carried out with version 4.2 of the program AutoDock (Morris at al., J Comput Chem., 19: 1639-1662, 1998.). Kollman's united atomic charges were computed. A grid box of 23×20×33 Å was constructed in, respectively, the x,y and z axes around the binding cavity. All ligand torsion angles were allowed to rotate during docking, leading to a complete flexibility. One hundred cycles of calculations of Lamarckian Genetic Algorithm were performed to complete the conformational search. 100 resulting docking structures were clustered into conformation families according to a RMSD lower than 2.0 Å. The inventors selected the conformation, which presented the lowest docking free energy of binding in the most populated cluster.
- Ex Vivo Experiments.
- Heterozygous Fgfr3Y367C/+ mice ubiquitously expressing the Y367C mutation and exhibiting a severe dwarfism were used (Pannier et al., Biochim Biophys Acta, 1792: 140-147, 2009). Six sets of ex vivo experiments were performed. Femur embryos at day E16.5 from WT (n=6) and Fgfr3Y367C/+ (n=6) mice were used and incubated for 5 days in DMEM medium with antibiotics and 0.2% BSA (Sigma) supplemented with A31 or PD173074 (as control) at a concentration of 2 mM. Right femur was cultured in supplemented medium and compared with the left one cultured in control medium. Rib cage from E16.5 WT and Fgfr3Y367C/+ mice embryos were isolated and stripped of all soft tissues. Primary chondrocytes were obtained from rib cages. The ribs were incubated in a pronase solution (Roche; 2 mg/ml) followed by a digestion in Collagenase A (Roche; 3 mg/ml) at 37° C. Isolated chondrocytes were plated out at a density of 2.105 cells in 6-well plates containing DMEM supplemented with 10% FCS and antibiotics, and were allowed to reach subconfluency. Cultures were supplemented with A31 or PD173074 (as control) at a concentration of 2 mM. Cells were treated with A31 (2 mM) PD173074 (as control) in serum-free DMEM supplemented with 0.2% BSA and harvested after 24 h. To establish the effect of the inhibitors, the right femur was cultured in supplemented medium and compared with the left one cultured in control medium The bone length was measured at the beginning (before treatment) and at the end of time course. Each experiment was repeated at least three times. The genotype of WT, Fgfr3Y367C/+ and Fgfr3−/− mice were determined by PCR of tail DNA as previously described (Pannier et al., Biochim Biophys Acta, 1792: 140-147, 2009). All experimental procedures and protocols were approved by the Animal Care and Use Committee.
- Histological, In Situ Hybridization and Immunohistochemical Analyses.
- Limb explants were fixed after culture in 4% paraformaldehyde at 4° C., and placed in a staining solution for 45-60 minutes (0.05% Alizarin Red, 0.015% Alcian Blue, 5% acetic acid in 70% ethanol) or embedded in paraffin. Serial mm?sections of 5 were stained with Hematoxylin-Eosin using standard protocols for histological analysis or were subjected to in situ hybridization or immunohistochemical staining.
- In situ hybridization using [S35]-UTP labeled antisense ribopropes for collagen X was carried out as previously described (Delezoide et al., Hum Mol Genet, 6, 1899-1906, 1997). Sections were counterstained with Hematoxylin. For immunohistochemistry, sections were stained with antibodies specific to FGFR3 (1:250 dilution; Sigma), anti PCNA (1:1000 dilution; Abcam), anti-KI67 (1:300; Abcam), anti-cyclin D1 (1:80 dilution; Santa Cruz) and anti-p57 (1:100 dilution; Santa Cruz) using the Dako Envision kit. Images were captured with an Olympus PD70-IX2-UCB microscope.
- Quantification of PCNA Expression.
- Three observers counted PCNA-positive and negative chondrocytes in proliferative (H), prehypertrophic (PH) and hypertrophic (H) zones of the growth plate. A Student's t-test was used to compare treated (A31) and untreated femurs. Imagine software cellSens (Olympus) was used for counting cells. A p-value <0.05 is considered significant.
- Immunoprecipiation, Immunoblotting and Immunocytochemistry Experiments.
- Human Embryonic Kidney (HEK) cells and human chondrocyte lines (Benoist-Lasselin at al., FEBS Lett, 581: 2593-2598, 2007.) were transfected transiently with FGFR3 human constructs (FGFR3Y373C, FGFR3K650M, FGFR3K650E) (Gibbs, L. and Legeai-Mallet, L. Biochim Biophys Acta, 1773: 502-512, 2007) using Fugene 6 (Roche). A31 (31) or PD173074 (Parke Davies) were added at a concentration of 2 mM overnight. Transfected cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.5% NP40, 0.25% sodium deoxycholate, supplemented with protease and phosphatase inhibitors).
- Immunoprecipitation were performed by incubating 3 mL rabbit anti-FGFR3 (Sigma)/500 mg protein with protein A-agarose (Roche). Immunoprecipitated proteins were subjected to SDS-polyacrylamide gel electrophoresis on NuPAGE 4-12% bis-tris acrylamide gels (Invitrogen). Immunoprecipitated proteins were subjected to SDSpolyacrilamide gels electrophoresis on NuPAGE 4-12% bis-tris acrylamide gels (Invitrogen). Blots were hybridized overnight at 4° C. with anti-FGFR3 polyclonal antibody (1:1,000 dilution; Sigma), or anti-phosphotyrosine monoclonal antibody (1:400 dilution; Cell Signaling). Lysates of primary murine chondrocytes (E16.5) were subjected to SDS-polyacrylamide gel electrophoresis and were hybridized overnight at 4° C. with anti-cyclin D1 monoclonal antibody (1:100 dilution; Santa Cruz). A secondary antibody, anti-rabbit or anti-mouse coupled to peroxidase, was used at a dilution of 1:10,000 (Amersham). Bound proteins were detected by chemiluminescence (ECL, Amersham). The blots were rehybrididized with an antipan-actin antibody for quantification (Millipore).
- For immunocytochemistry, the inventors used the following primary antibodies: anti-FGFR3 antibodies (1:400 dilution; Sigma) and anti-phosphotyrosine antibodies (1:200 dilution; Cell Signaling) and secondary antibodies Alexa Fluor®488 goat antirabbit and Alexa Fluor®568 goat anti-mouse (1:400 dilution; Molecular Probes). Cells were covered with Faramount Aquaeous Mounting Medium (Dako) and analyzed using an Olympus PD70-IX2-UCB microscope.
- Proliferation Studies.
- NIH-3T3 clones stably expressing FGFR3+/+ (WVT) and FGFR3Y373C, FGFR3K650M (human constructs) were used. The stable clones were selected with G418. NIH-3T3 clones were incubated for 8 h in 10% newborn calf serum DMEM supplemented or not with A31 (2 mM). [3H] thymidine was added at a concentration of 10 mCi/ml and incubated for 16 hours. The cells were harvested on glass fiber filter paper and assayed for radioactivity by liquid scintillation counting. The inventors used Top Count Microplates scintillation counter (Perkin Elmer).
- In Vivo Experiments.
- The effectiveness of PD173074 and BGJ-398 in attenuating the dwarfism phenotype of Fgfr3Y367C/+ mice was assessed in vivo. The mice were seven days of age at treatment initiation and received daily subcutaneous administration of 4.00 mg/kg PD173074 or of 1.66 mg/kg BGJ-398 for 10 days.
- Computational analyses were used to estimate interactions between FGFR3 and A31, a synthetic compound of the pyrido-[2,3-d] pyrimidine class, as a novel FGFR3 tyrosine kinase inhibitor (TKI) (
FIG. 1A ). To date, attempts to determine the experimental Xray structure of the FGFR3 kinase domain have failed. To overcome this drawback, the inventors predicted the structure of FGFR3 in silico by using a new crystal structure of the highly homologous FGFR1 (Ravindranathan et al., J Med Chem, 53: 1662-1672, 2010). The resulting 3D structure of FGFR3 showed a low global energy and negative electrostatic and Van der Waals components indicating a high level of confidence for this prediction. Docking calculations were used to find the optimal position of A31 in the binding pocket of FGFR3. The interactions between the FGFR3 kinase domain and A31 are depicted inFIG. 1B . The aromatic group carrying the two methoxy moieties and the biphenyl ring induce strong interactions between the FGFR3 kinase domain and A31. Two hydrogen bonds locate the biphenyl ring at the adenine position of ATP, filling the FGFR3 active site and, in this way, A31 competes directly with the substrate. The cyclic amino tail of A31 is deeply nestled inside the FGFR3 cavity in the vicinity of a protein salt bridge. As a consequence, the salt bridge is disrupted, thus preventing the kinase activity of FGFR3. These in-silico data suggest that A31 specifically inhibits FGFR3 kinase activity. - The inventors evaluated the ability of A31 to inhibit the constitutive phosphorylation of FGFR3 in human chondrocyte lines (Gibbs, L. and Legeai-Mallet, L. Biochim Biophys Acta, 1773: 502-512, 2007) transiently expressing activated forms of FGFR3 (FGFR3Y373C or FGFR3K650E (TD), FGFR3K650M (SADDAN) or FGFR3+/+).
- Immunoprecipitation and Western blotting showed the presence of a 130 kDa mature isoform in the WT and FGFR3Y373C cell lysates, whereas only an 115 kDa immature form was present in FGFR3K650M and FGFR3K650E lysates (
FIG. 2 ). A31, abolished receptor phosphorylation in all cells expressing FGFR3 mutations (FIG. 2 ). Similar results were found with a commercial TKI inhibitor (PD173074) (FIG. 2 ). This inhibition was confirmed by immunocytochemistry in transfected cells expressing FGFR3 mutations (data not shown). The inventors observed a complete inhibition of FGFR3 phosphorylation by A31. - This data confirmed the ability of A31 to inhibit constitutive FGFR3 phosphorylation in transfected cells. To determine whether A31 modulates the mitogenic activity of activated FGFR3, the inventors measured [3H]-thymidine incorporation in FGFR3Y373C and FGFR3K650M transfected NIH3T3 cells. The mitogenic activity was increased in cells expressing FGFR3 mutations compared to WT (FGFR3Y373C, 9927±2921 cpm; FGFR3K650M, 15048±5251 cpm; WT, 7499±1667 cpm; p<10−5 versus WT).
- A31 treatment strongly reduced DNA synthesis of all mutant cell lines (FGFR3Y373C, 3144±1201 cpm; FGFR3K650M, 6281±2699 cpm; **p<10−10, ***p<10−20 versus DMSO). These results demonstrate that A31 decreases the mitogenic activity of FGFR3 mutants.
- To confirm these results, the ability of BGJ-398 (also designated as compound 1h in Table B), another tyrosine kinase inhibitor, to inhibit the constitutive phosphorylation of FGFR3 in cells (HEK-293) transiently expressing activated forms of FGFR3 (i.e. FGFR3Y373C, FGFR3K650E, FGFR3K650M, FGFR3G380R) was also tested. It was found that 10 μM of BGJ-398 abolished receptor phosphorylation in all cells expressing FGFR3 mutations (data not shown).
- A31 was tested on a gain of function Fgfr3Y367C/+ mouse model (Pannier et al., Biochim Biophys Acta, 1792: 140-147, 2009). It is to be noted that mutation Y367C in mouse FGFR3 corresponds to mutation Y373C in human FGFR3.
- Fgfr3Y367C/+ mice display reduced length of long bones, broad femurs, a narrow trunk, short ribs and a slightly dome-shaped skull, closely resembling achondroplasia (
FIGS. 3A and B). The inventors analyzed the effects of A31 on endochondral ossification in Fgfr3Y367C/+ mice by using an ex vivo culture system for embryonic day 16.5 (E16.5) limb explants. Mutant femurs cultured without A31 had a significantly reduced longitudinal growth compared to WT (Fgfr3Y367C/+, 461±119 μm; WT, 1247±226 μm; p<10−10) (FIGS. 3C and D). A31 was able to induce and fully restore limb growth in Fgfr3Y367C/+ femurs (Fgfr3Y367C/+, gain of 1880±558 μm; WT, 1863±255 μm; p<10−19) (FIGS. 3C and D). After 5 days of culture, the increase in length of the treated mutant femurs was 2.6 times more than for that of WT. - Histological examinations using HES staining (
FIG. 4A ) and type X collagen labeling (FIG. 4B ), revealed a reduction in size of the hypertrophic zone of the Fgfr3Y367C/+ mouse growth plate (FIG. 4B ), with abnormally small chondrocytes resembling prehypertrophic rather than hypertrophic cells. The inventors evaluated the impact of A31 on the growth plate (FIG. 4A ). Interestingly, A31 induced a marked expansion of the hypertrophic zone, with marked modifications of the shape of proliferative and hypertrophic cells. A31-treated chondrocytes appeared enlarged and more spherical, resembling to hypertrophic chondrocytes (data not shown). Therefore, these results suggest that A31 increased the size of mutant growth plates by restoring the disrupted chondrocyte maturation process. - To confirm the results obtained with tyrosine kinase inhibitor “A31”, another FGFR3 belonging to the pyrido[2,3-d]pyrimidine class, i.e. the tyrosine kinase inhibitor “PD173074”, was also tested.
- Thus, embryonic femur explants were co-incubated with 150 nM of PD173074 for 5 days.
- As illustrated by the gain in femur length, PD173074 for 5 days is sufficient for correcting the difference in length and normalized the size of the epiphyses PD173074 enhances longitudinal growth in Fgfr3Y367C/+ femurs (gain of 77%; see
FIGS. 7 (A) and (B); mutant femurs cultured without PD173074 had a reduced longitudinal growth compared to WT femurs (Fgfr3+/+). The effect of PD173074 on femur growth is similar to that of A31 (seeFIGS. 7 (A) and (B)). - Similar experiments were conducted with an antagonist which belongs to the N-aryl-N′-pyrimidin-4-yl urea class, i.e. the tyrosine kinase inhibitor “BGJ-398”.
- Embryonic femur explants were co-incubated 100 nM (10−7M) or 1 μM (10−6M) of BGJ-398 for 6 days.
- A concentration-dependent increase in femur size was observed for BGJ-398 concentrations ranging from 100 nM to 1 μM, as illustrated by the gain in femur length. 100 nM of BGJ-398 for 6 days is sufficient for correcting the difference in length and normalized the size of the epiphyses. A gain of 71.86% is observed in treated Fgfr3Y367C/+ femurs (
FIG. 9 ; mutant femurs cultured without BGJ-398 had a reduced longitudinal growth compared to WT femurs (Fgfr3+/+). - Histological examinations using HES staining (
FIG. 10A ) and type X collagen labeling (FIG. 10B ) were also carried out. - HES staining of WT (Fgfr3+/+) and Fgfr3Y367C/+ mice showed that growth plate from Fgfr3Y367C/+ mice have smaller mutant chondrocytes, whereas cells are larger and more spherical when femurs are cultured in the presence of 10−6M of BGJ-398 (
FIG. 10A ). -
FIG. 10B shows that BGJ-398 induces enhanced type X collagen expression in Fgfr3Y367C/+ growth plate and that the size of the hypertrophic zone of the femur explants of Fgfr3Y367C/+ mice increases. - Taken together, these results showed histological changes (increased chondrocyte proliferation and differentiation) when femurs from Fgfr3Y367C/+ mice are cultivated in the presence of BGJ-398.
- The inventors evaluated the level of Fgfr3 protein expression by immunohistochemical staining and found an overexpression of Fgfr3 in Fgfr3Y367C/+ growth plates. A31 induced a large decrease of Fgfr3 expression in mutant femurs (data not shown). These results were confirmed by Western blotting on primary chondrocytes isolated from E16.5 ribs (
FIG. 5 ). A higher level of Fgfr3 was revealed in untreated Fgfr3Y367C/+ chondrocytes, whereas this level was similar to WT after addition of A31. These data indicate that inhibition of the constitutive phosphorylation of Fgfr3 by A31 rescues the turnover of the receptor. - Analysis of expression of Proliferating Cell Nuclear Antigen (PCNA), an Sphase marker, revealed abnormally high levels of PCNA in the prehypertrophic (PH) (73% of total cells positive; p<0.005) and hypertrophic (H) areas of Fgfr3Y367C/+ mouse growth plates (43% of total cells positive; p<0.005). A31 strongly decreased PCNA expression in the corresponding areas of mutant growth plates (20% and 18% for PH and H areas, respectively, ***p<10−4) (
FIG. 6A ). Likewise, higher expression levels of KI67 were observed in the PH and H areas of Fgfr3Y367C/+ mouse growth plates compared to controls (data not shown). A31 also decreased this expression in Fgfr3Y367C/+ mouse growth plates (data not shown). The inventors noted a higher expression of PCNA than KI67 in the mutant growth plate. Furthermore, the inventors investigated whether the presence of mutated Fgfr3 caused an impairment of expression of cell cycle regulators. In fact, activated Fgfr3 induced a significant overexpression of cyclin D1 in the proliferative and PH chondrocytes of Fgfr3Y367C/+ mice. Interestingly, A31 returned cyclin D1 expression to control levels in mutant femurs (data not shown). Consistent with this Western blots showed a reduced level of cyclin D1 in A31-treated murine chondrocytes isolated from E16.5 ribs compared to untreated chondrocytes (FIG. 6B ). The inventors further analyzed the level of CDK inhibitors (CDKIs) negatively regulating the cell cycle, particularly p57, a member of the Cip/Kip family. Activated Fgfr3 induced a higher expression of p57 predominantly in late proliferative and PH chondrocytes. A31 reduced expression of p57 protein particularly in the PH zone and enabled PH chondrocytes to properly differentiate into H chondrocytes (data not shown). The inventors conclude that activated FGFR3 leads to over-expression of markers of proliferation (PCNA, KI67) and cell cycle regulators (cyclin D1 and p57) particularly in the prehypertrophic zone. These data highlight the dysregulation of the cell cycle in this skeletal pathology. - The effectiveness of PD173074 in attenuating the dwarfism phenotype of Fgfr3Y367C/+ mice was assessed in vivo. The mice were seven days of age at treatment initiation and received daily subcutaneous administrations of 4.00 mg/kg of PD173074 for 10 days.
- Results of this experiment are disclosed in
FIG. 8 which is an X-rays analysis of Fgfr3Y367C/+ mice administered with PD173074 or with a vehicule (“mock” experiment). Amelioration in key relevant achondroplasia clinical features including bowed femur and tibia, anterior crossbite and domed skull was observed (seeFIGS. 8A and B; compare PD173074-treated mouse on the left side of panels A and B vs vehicule-administered mouse on the right side of panels A and B). Indeed, dramatic phenotypic changes are observed, including larger paws and digits, and longer and straightened tibia and femurs in Fgfr3Y367C/+ mouse treated with PD173074. - Therefore, improvement in the dwarfism was obvious after 10 days of treatment in animals given 4.00 mg/kg PD173074 and included an overall increase in body size with longer tail and snout.
- Seven days old mice received daily subcutaneous administrations of 1.66 mg/kg of BGJ-398 for 10 days.
- Dramatic phenotypic changes are observed, including larger paws and digits, and longer and straightened tibia and femurs in Fgfr3Y367C/+ mouse treated with BGJ-398 (see
FIG. 11 which is an X-rays of Fgfr3Y367C/+ mice administered with BGJ-398—mouse on the left side of the figure—or with a vehicule (“mock” experiment)—mouse on the right side of the figure).
Claims (2)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/872,307 US20180161327A1 (en) | 2011-12-12 | 2018-01-16 | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
US16/662,126 US11357778B2 (en) | 2011-12-12 | 2019-10-24 | Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3 |
US17/734,331 US20230075776A1 (en) | 2011-12-12 | 2022-05-02 | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2011/003254 WO2013088192A1 (en) | 2011-12-12 | 2011-12-12 | Plastic compositions and containers made thereof |
IBPCT/IB2011/003254 | 2011-12-12 | ||
PCT/EP2012/075294 WO2013087725A1 (en) | 2011-12-12 | 2012-12-12 | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
US201414364320A | 2014-06-11 | 2014-06-11 | |
US14/844,041 US9931341B2 (en) | 2011-12-12 | 2015-09-03 | Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3 |
US15/872,307 US20180161327A1 (en) | 2011-12-12 | 2018-01-16 | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/844,041 Continuation US9931341B2 (en) | 2011-12-12 | 2015-09-03 | Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/662,126 Continuation US11357778B2 (en) | 2011-12-12 | 2019-10-24 | Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180161327A1 true US20180161327A1 (en) | 2018-06-14 |
Family
ID=45722665
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/364,314 Expired - Fee Related US9133328B2 (en) | 2011-12-12 | 2011-12-12 | Plastic compositions and containers made thereof |
US14/844,041 Active US9931341B2 (en) | 2011-12-12 | 2015-09-03 | Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3 |
US15/872,307 Abandoned US20180161327A1 (en) | 2011-12-12 | 2018-01-16 | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
US16/662,126 Active US11357778B2 (en) | 2011-12-12 | 2019-10-24 | Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/364,314 Expired - Fee Related US9133328B2 (en) | 2011-12-12 | 2011-12-12 | Plastic compositions and containers made thereof |
US14/844,041 Active US9931341B2 (en) | 2011-12-12 | 2015-09-03 | Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/662,126 Active US11357778B2 (en) | 2011-12-12 | 2019-10-24 | Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3 |
Country Status (3)
Country | Link |
---|---|
US (4) | US9133328B2 (en) |
EP (1) | EP2791242A1 (en) |
WO (1) | WO2013088192A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
WO2020210451A1 (en) * | 2019-04-10 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | Degraders of fibroblast growth factor receptor 2 (fgfr2) |
WO2021250198A1 (en) * | 2020-06-11 | 2021-12-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of fgfr3-related cognitive deficit |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7390370B2 (en) * | 2018-09-28 | 2023-12-01 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Infigratinib for the treatment of FGFR3-related bone disease during pregnancy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9223781D0 (en) * | 1992-11-13 | 1993-01-06 | Woodhams Raymond T | Cellulose reinforced oriented thermoplastic composites |
ES2280218T5 (en) | 1999-05-05 | 2010-05-14 | Institut Curie | MEANS OF DETECTION AND TREATMENT OF PATHOLOGIES ASSOCIATED WITH FGFR3. |
WO2002102854A2 (en) | 2001-06-20 | 2002-12-27 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
WO2007061130A1 (en) | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
US20110166223A1 (en) | 2008-08-19 | 2011-07-07 | Cedars-Sinai Medical Center | Methods of inhibiting fgfr3 signaling |
CN101875746B (en) * | 2010-05-14 | 2013-07-31 | 广州金发绿可木塑科技有限公司 | Styrene series non-halogen flame retardant injection-grade wood plastic composite and preparation method thereof |
-
2011
- 2011-12-12 US US14/364,314 patent/US9133328B2/en not_active Expired - Fee Related
- 2011-12-12 EP EP11819169.1A patent/EP2791242A1/en not_active Withdrawn
- 2011-12-12 WO PCT/IB2011/003254 patent/WO2013088192A1/en active Application Filing
-
2015
- 2015-09-03 US US14/844,041 patent/US9931341B2/en active Active
-
2018
- 2018-01-16 US US15/872,307 patent/US20180161327A1/en not_active Abandoned
-
2019
- 2019-10-24 US US16/662,126 patent/US11357778B2/en active Active
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
WO2020210451A1 (en) * | 2019-04-10 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | Degraders of fibroblast growth factor receptor 2 (fgfr2) |
CN113747894A (en) * | 2019-04-10 | 2021-12-03 | 丹娜-法伯癌症研究公司 | Degradation agent for fibroblast growth factor receptor 2(FGFR2) |
WO2021250198A1 (en) * | 2020-06-11 | 2021-12-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of fgfr3-related cognitive deficit |
Also Published As
Publication number | Publication date |
---|---|
EP2791242A1 (en) | 2014-10-22 |
WO2013088192A1 (en) | 2013-06-20 |
US9133328B2 (en) | 2015-09-15 |
US11357778B2 (en) | 2022-06-14 |
US20160051549A1 (en) | 2016-02-25 |
US20200246337A1 (en) | 2020-08-06 |
US20140371355A1 (en) | 2014-12-18 |
US20220031696A9 (en) | 2022-02-03 |
US9931341B2 (en) | 2018-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230075776A1 (en) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 | |
US11357778B2 (en) | Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3 | |
Gohil et al. | FGF23 and associated disorders of phosphate wasting | |
Li et al. | Tyrosine kinase Fyn promotes osteoarthritis by activating the β-catenin pathway | |
Suen et al. | Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review | |
Sandri et al. | Signalling pathways regulating muscle mass in ageing skeletal muscle. The role of the IGF1-Akt-mTOR-FoxO pathway | |
Boudin et al. | The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases | |
Bruzzaniti et al. | Molecular regulation of osteoclast activity | |
Imel et al. | Fibroblast growth factor 23: roles in health and disease | |
US8183225B2 (en) | Inhibition of bone resorption using medical implants containing adenosine receptor antagonists | |
US7888372B2 (en) | Compositions and methods for modulating bone mineral deposition | |
Yavropoulou et al. | The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis | |
US20020183276A1 (en) | Compositions and methods for modulating bone mineral deposition | |
Fuchs et al. | Sef is an inhibitor of proinflammatory cytokine signaling, acting by cytoplasmic sequestration of NF-κB | |
Yao et al. | Protein kinase C inhibitor, GF109203X attenuates osteoclastogenesis, bone resorption and RANKL‐induced NF‐κB and NFAT activity | |
Ribet et al. | Membrane transport proteins in osteoclasts: the ins and outs | |
US20200306244A1 (en) | Wnt inhibitors for use in the treatment of fibrosis | |
US9937173B2 (en) | Method of treating obesity | |
Dierschke et al. | Angiotensin-(1–7) attenuates protein O-GlcNAcylation in the retina by Epac/Rap1-dependent inhibition of O-GlcNAc transferase | |
US20060094013A1 (en) | Salt-inducible kinases 2 and use thereof | |
Gogakos et al. | Bone signaling pathways and treatment of osteoporosis | |
EP4171560A1 (en) | A new combination therapy for the treatment of fgfr3- related skeletal disease | |
Xue et al. | SLC4A2, another gene involved in acid-base balancing machinery of osteoclasts, causes osteopetrosis | |
Sosa et al. | Promising developments in osteoporosis treatment | |
US20230220037A1 (en) | Novel use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUNNICH, ARNOLD;BUSCA, PATRICIA;BARBAULT, FLORENT;SIGNING DATES FROM 20150402 TO 20150409;REEL/FRAME:044628/0499 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LEGEAI-MALLET, LAURENCE;REEL/FRAME:044628/0320 Effective date: 20140406 Owner name: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUNNICH, ARNOLD;BUSCA, PATRICIA;BARBAULT, FLORENT;SIGNING DATES FROM 20150402 TO 20150409;REEL/FRAME:044628/0499 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUNNICH, ARNOLD;BUSCA, PATRICIA;BARBAULT, FLORENT;SIGNING DATES FROM 20150402 TO 20150409;REEL/FRAME:044628/0499 Owner name: IMAGINE, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUNNICH, ARNOLD;BUSCA, PATRICIA;BARBAULT, FLORENT;SIGNING DATES FROM 20150402 TO 20150409;REEL/FRAME:044628/0499 Owner name: UNIVERSITE PARIS DESCARTES, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUNNICH, ARNOLD;BUSCA, PATRICIA;BARBAULT, FLORENT;SIGNING DATES FROM 20150402 TO 20150409;REEL/FRAME:044628/0499 Owner name: UNIVERSITE PARIS DIDEROT - PARIS 7, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUNNICH, ARNOLD;BUSCA, PATRICIA;BARBAULT, FLORENT;SIGNING DATES FROM 20150402 TO 20150409;REEL/FRAME:044628/0499 |
|
AS | Assignment |
Owner name: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);REEL/FRAME:044642/0346 Effective date: 20140829 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);REEL/FRAME:044642/0346 Effective date: 20140829 Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);REEL/FRAME:044642/0346 Effective date: 20140829 Owner name: UNIVERSITE PARIS DESCARTES, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);REEL/FRAME:044642/0346 Effective date: 20140829 Owner name: UNIVERSITE PARIS DIDEROT - PARIS 7, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);REEL/FRAME:044642/0346 Effective date: 20140829 Owner name: IMAGINE, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);REEL/FRAME:044642/0346 Effective date: 20140829 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |